Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells.

Djouad F, Bony C, Apparailly F, Louis-Plence P, Jorgensen C, Noël D.

Transplantation. 2006 Oct 27;82(8):1060-6.

PMID:
17060855
2.

Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals.

Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Noël D, Jorgensen C.

Blood. 2003 Nov 15;102(10):3837-44. Epub 2003 Jul 24.

3.

Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy.

Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C.

Cancer Res. 2007 Jul 1;67(13):6304-13.

4.

Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.

Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M.

J Natl Cancer Inst. 2004 Nov 3;96(21):1593-603.

PMID:
15523088
5.

Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice.

Kucerova L, Matuskova M, Pastorakova A, Tyciakova S, Jakubikova J, Bohovic R, Altanerova V, Altaner C.

J Gene Med. 2008 Oct;10(10):1071-82. doi: 10.1002/jgm.1239.

PMID:
18671316
6.

Development of sarcomas in mice implanted with mesenchymal stem cells seeded onto bioscaffolds.

Tasso R, Augello A, Carida' M, Postiglione F, Tibiletti MG, Bernasconi B, Astigiano S, Fais F, Truini M, Cancedda R, Pennesi G.

Carcinogenesis. 2009 Jan;30(1):150-7. doi: 10.1093/carcin/bgn234. Epub 2008 Oct 9.

PMID:
18849298
7.

Mesenchymal stem cell-mediated immature dendritic cells induce regulatory T cell-based immunosuppressive effect.

Choi YS, Jeong JA, Lim DS.

Immunol Invest. 2012;41(2):214-29. doi: 10.3109/08820139.2011.619022. Epub 2011 Oct 21.

PMID:
22017637
8.

Allogeneic injection of fetal membrane-derived mesenchymal stem cells induces therapeutic angiogenesis in a rat model of hind limb ischemia.

Ishikane S, Ohnishi S, Yamahara K, Sada M, Harada K, Mishima K, Iwasaki K, Fujiwara M, Kitamura S, Nagaya N, Ikeda T.

Stem Cells. 2008 Oct;26(10):2625-33. doi: 10.1634/stemcells.2008-0236. Epub 2008 Jul 31.

9.

[Inhibitory effect of mesenchymal stem cells carrying murine beta defensin 2 on malignant ascites in mice].

Wang GQ, Xu JR, Wang R, Li HX, Xu N, Du XB, Wei YQ.

Ai Zheng. 2006 Jun;25(6):657-62. Chinese.

PMID:
16764757
10.

Intratracheal delivery of CX3CL1-expressing mesenchymal stem cells to multiple lung tumors.

Xin H, Sun R, Kanehira M, Takahata T, Itoh J, Mizuguchi H, Saijo Y.

Mol Med. 2009 Sep-Oct;15(9-10):321-7. doi: 10.2119/molmed.2009.00059. Epub 2009 Jun 18.

11.

Treatment of transforming growth factor-beta-insensitive mouse Renca tumor by transforming growth factor-beta elimination.

Perry K, Wong L, Liu V, Park I, Zhang Q, Rejen V, Huang X, Smith ND, Jovanovic B, Lonning S, Teicher BA, Lee C.

Urology. 2008 Jul;72(1):225-9. doi: 10.1016/j.urology.2007.11.091. Epub 2008 Mar 4.

PMID:
18295867
12.

The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo.

Lu YR, Yuan Y, Wang XJ, Wei LL, Chen YN, Cong C, Li SF, Long D, Tan WD, Mao YQ, Zhang J, Li YP, Cheng JQ.

Cancer Biol Ther. 2008 Feb;7(2):245-51. Epub 2007 Nov 14.

PMID:
18059192
13.
14.

IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells.

English K, Barry FP, Field-Corbett CP, Mahon BP.

Immunol Lett. 2007 Jun 15;110(2):91-100. Epub 2007 Apr 26.

PMID:
17507101
15.

Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor.

Fritz V, Noël D, Bouquet C, Opolon P, Voide R, Apparailly F, Louis-Plence P, Bouffi C, Drissi H, Xie C, Perricaudet M, Müller R, Schwarz E, Jorgensen C.

Stem Cells. 2008 Nov;26(11):2981-90. doi: 10.1634/stemcells.2008-0139. Epub 2008 Aug 28.

16.

Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells.

Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, Barry FP, O'Brien T, Kerin MJ.

Clin Cancer Res. 2007 Sep 1;13(17):5020-7.

17.

Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells.

Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, Cavinato RA, Todeschini M, Solini S, Sonzogni A, Perico N, Remuzzi G, Noris M.

J Immunol. 2008 Sep 15;181(6):3933-46.

18.
19.

Is immunosuppression at the tumor site mechanism of evasion of a systemic response?

Karakousis CP, Sharma S, Brooks SP.

J Med. 2003;34(1-6):3-14.

PMID:
17682306
20.

No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients.

Sundin M, Ringdén O, Sundberg B, Nava S, Götherström C, Le Blanc K.

Haematologica. 2007 Sep;92(9):1208-15. Epub 2007 Aug 1.

Supplemental Content

Support Center